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Abstract
Heterozygous germline mutations and deletions in PHOX2B, a key regulator of autonomic neuron development, predispose
to neuroblastoma, a tumor of the peripheral sympathetic nervous system. To gain insight into the oncogenic mechanisms
engaged by these changes, we used zebrafish models to study the functional consequences of aberrant PHOX2B expression
in the cells of the developing sympathetic nervous system. Allelic deficiency, modeled by phox2b morpholino knockdown,
led to a decrease in the terminal differentiation markers th and dbh in sympathetic ganglion cells. The same effect was seen
on overexpression of two distinct neuroblastoma-associated frameshift mutations, 676delG and K155X - but not the R100L
missense mutation - in the presence of endogenous Phox2b, pointing to their dominant-negative effects. We demonstrate
that Phox2b is capable of regulating itself as well as ascl1, and that phox2b deficiency uncouples this autoregulatory
mechanism, leading to inhibition of sympathetic neuron differentiation. This effect on terminal differentiation is associated
with an increased number of phox2b+, ascl1+, elavl32 cells that respond poorly to retinoic acid. These findings suggest that a
reduced dosage of PHOX2B during development, through either a heterozygous deletion or dominant-negative mutation,
imposes a block in the differentiation of sympathetic neuronal precursors, resulting in a cell population that is likely to be
susceptible to secondary transforming events.
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Introduction
Neuroblastoma is an embryonal malignancy of the peripheral
sympathetic nervous system (PSNS) that arises from the develop-
ing neural crest and manifests as neoplasms in sympathetic ganglia
or adrenal medulla. The oncogenic events culminating in
neuroblastoma are thought to occur very early in development,
consistent with the status of this tumor as the most common cancer
of infants [1]. A defining feature of neuroblastic tumors is their
broad spectrum of cellular differentiation, ranging from undiffer-
entiated cells that indicate a poor prognosis to those showing
greater differentiation and predicting a generally favorable
outcome [2]. This heterogeneity suggests that dysregulated
differentiation of sympathetic progenitor cells plays a key role in
neuroblastoma pathogenesis. Direct evidence for this model comes
from the identification of heterozygous germline mutations in the
homeodomain transcription factor PHOX2B, a regulator of
sympathetic neuronal differentiation [3–8]. Such mutations are
also found in patients with other neural crest-derived disorders,
including congenital central hypoventilation syndrome (CCHS)
and Hirschprung’s disease, characterized by absent or abnormal
development of the noradrenergic neurons in the brain stem and
colon, respectively [3,5,7,8].
The vast majority of embryonal tumors like neuroblastoma arise
from aberrant genetic and epigenetic changes that control the
survival, proliferation and differentiation of specific tissues. Hence,
one way to decipher the tumorigenic contribution of germline
changes in highly conserved genes such as PHOX2B is to
understand how they perturb normal development. The sympa-
thetic nervous system is derived from the neural crest, a
multipotent embryonic structure consisting of a transient popula-
tion of cells that migrate from the neural tube to the region of the
dorsal aorta during development [9–11]. At the dorsal aorta,
prespecified SOX10-positive sympathetic progenitors, under the
influence of bone morphogenetic proteins (BMPs), start the process
of differentiation into noradrenergic neurons [12]. Phox2b and the
basic helix-loop-helix (bHLH) factor Ascl1 are the first transcrip-
tion factors that appear upon initiation of differentiation of
sympathoadrenal precursors [13–15]. Phox2a is expressed down-
stream of both Phoxb and Ascl1 [13,16,17] but its role in the initial
stages of the sympathetic lineage remains undefined. Further
neuronal differentiation occurs under the influence of the
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transcription factors Hand2 [18,19], Gata2/3 [20] and Tfap2a
[21,22], which interact in a complex regulatory network to
ultimately induce the expression of tyrosine hydroxylase (Th) and
dopamine beta hydroxylase (Dbh) - two enzymes required for
catecholamine production that serve as markers of terminal
sympathetic neuronal differentiation [23–25]
Extensive work in murine and avian models has established
Phox2b as a key regulator of autonomic neuron development, as its
complete absence leads to embryonic lethality in mice due to the
failure of sympathetic nervous system formation [15,26]. Phox2b is
first expressed in the murine peripheral sympathetic primordial at
the dorsal aorta at E10.5 [13,27]. By E13.5, it is expressed in all
sympathetic progenitor cells including those of the superior
cervical ganglia, paravertebral and pelvic ganglia and the adrenal
medulla [27], and expression continues into the early postnatal
period [28]. As the ganglia/adrenal medullae mature and the
sympathoblasts differentiate, TH- and DBH-expression increases
while PHOX2B expression decreases, so that by P28, only 12% of
TH-positive sympathetic neurons have PHOX2B expression
(compared to approximately 60% at P4) [28]. Hence, Phox2b is
downregulated during terminal neuronal differentiation [28].
Phox2b also has growth inhibitory effects, as its overexpression
promotes cell cycle exit and inhibits the proliferation of cultured
sympathetic neurons [29,30]. Most of the activity of the Phox2b
promoter depends on an autoregulatory loop enabling the gene to
regulate its own activity and that of other genes [31].
The human PHOX2B gene maps to chromosome 4p13 and
consists of three exons encoding a highly conserved 314–amino-
acid protein with two polyalanine repeats of 9 and 20 residues C-
terminal to the homeodomain. Unlike the case in CCHS, which is
defined largely by polyalanine repeat expansion mutations that
lead to expansion of the second polyalanine tract [8,32,33],
germline PHOX2B mutations associated with neuroblastoma tend
to be (i) missense alterations in highly conserved regions [4,7,33] or
(ii) mutations that result in a frameshift, giving rise to an altered or
truncated protein lacking the second polyalanine motif
[5,8,33,34]. More recently, whole-allele deletions resulting in the
reduction of the protein have been reported [35]. Still, the
mechanisms by which these different classes of alterations
predispose individuals to tumor development in the PSNS remain
somewhat unclear. Partial loss of function with the preserved
ability to suppress cellular proliferation but not to promote
differentiation [36], complete loss of function due to functional
haploinsufficiency [37] and both dominant-negative and gain-of-
function effects [30,34,38] have all been proposed as contributors
to neuroblastoma predisposition. In the single in vivo study to
date, heterozygous insertion of two frameshift variants, 931del5
and 693del8, in the mouse Phox2b locus resulted in impaired
proliferation of sympathetic ganglion progenitors and biased
differentiation towards the glial lineage, leading the authors to
conclude that these mutants exhibited both dominant-negative
and gain-of-function effects [38].
In this study we sought to analyze the effects of aberrant PHOX2B
expression on sympathetic neuron development for each of the
major classes of neuroblastoma-associated mutants. We selected the
zebrafish model for this purpose because its development occurs ex
utero, and the embryos survive considerably longer than mouse
embryos, permitting analysis of the PSNS at later stages of
sympathetic neuron differentiation and maintenance [39]. We
show here that allelic PHOX2B deletion, modeled by morpholino
(MO) knockdown, leads to a decrease in sympathetic neuronal
differentiation in the PSNS. A similar loss of differentiation was
observed upon overexpression of a neuroblastoma-linked truncation
mutation (K155X) [8] and a frameshift mutation (676delG) [5] in the
presence of endogenous phox2b, indicating that these variants
function in a dominant-negative manner. By contrast, the R100L
missense mutation [7] lacked any discernible effect on sympathetic
ganglion development in the zebrafish embryo. We demonstrate
further that the decrease in terminal differentiation was associated
with an increased number of undifferentiated sympathetic neuronal
precursors that were resistant to the effects of retinoic acid (RA), and
generated a pool of developmentally arrested cells that could serve
as targets for future transforming events.
Results
phox2b is expressed in cells of the PSNS in the zebrafish
To establish the zebrafish as a model for studying PHOX2B
function in PSNS development, we analyzed expression of the
phox2b gene in the superior cervical ganglion (SCG). The SCG is
the earliest sympathetic ganglion to develop, starting at about
36 hours postfertilization (hpf) and progressing in size until about 4
days postfertilization (dpf) (Figure 1A–1D) [18,21,39,40]. SCG
cells are located ventral to the notochord between somites 1 and 4
and are easily visualized as several smaller cell aggregates that
progressively increase in size, ultimately forming two separate
ganglia in an hourglass shape. phox2b expression is first seen in the
SCG cells at 36 hpf extending caudally in two irregular parallel
rows to form the primary sympathetic ganglion chain to somite 11
(Figure 1A–1D). It remains robust in the SCG until 72 hpf
(Figure 1C) when it gradually begins to be replaced by increasing
numbers of cells expressing dbh and th, markers of terminal
differentiation (Figures 1E–1F), whose expression is first seen at
about 48hpf. This expression pattern, especially in the peripheral
sympathetic ganglia, and the close sequence homology with
human PHOX2B [41] (Figure S1) support the use of the zebrafish
to model PHOX2B function in the PSNS.
phox2b deficiency leads to decreased PSNS
differentiation
To study the consequences of allelic PHOX2B deletion in
patients with neuroblastoma [35], we performed morpholino
Author Summary
Neuroblastoma, a tumor of the peripheral sympathetic
nervous system, is the most common cancer diagnosed in
infancy. Although most cases arise sporadically, familial
predisposition also occurs in association with mutations in
a single copy of the PHOX2B gene, a ‘‘master regulator’’ of
sympathetic neuronal development. The exact mecha-
nisms by which these mutations increase susceptibility to
neuroblastoma are unclear, primarily because of the
paucity of optimal models in which to study very early
development of the sympathetic nervous system. We took
advantage of the ex vivo development and transparent
nature of zebrafish embryos to study the roles of both
normal and mutated PHOX2B in development of the
sympathetic nervous system. We present data indicating
that aberrant PHOX2B expression causes an arrest in the
normal maturation of sympathetic neurons, leading to
immature cells that are resistant to drug-induced differ-
entiation. Indeed, we demonstrate that phox2b gene
‘‘dosage’’ is important for normal differentiation of
sympathetic neurons in the zebrafish and suggest that
the population of immature cells resulting from a
decreased dosage of this pivotal factor may be susceptible
to secondary mutations that could ultimately lead to
neuroblastoma.
PHOX2B Mutations Impair PSNS Differentiation
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(MO) knockdown of zebrafish phox2b, using two non-overlapping
antisense oligonucleotide sequences targeted to the phox2b gene: a
translation-blocking MO (MOATG) and a splice-blocking MO
(MOsplice) directed to the second exon/intron splice junction
(Figure S2A). phox2b knockdown was confirmed by immunoblot-
ting in the case of the ATG MO (which showed ,70–80%
knockdown) and RT-PCR for the splice MO (Figure S2B).
Experiments were performed in both wild-type and p53 mutant
embryos (tp53M214K/M214K) [42] to account for potential nonspe-
cific effects associated with some MO injections, with similar
results obtained in both backgrounds (Figure S2C). MO knock-
down of phox2b led to a marked reduction in th and dbh expression
in the SCG at 3 dpf, as compared with mismatched control MO-
injected (MOMM) or uninjected wild-type (WT) siblings (Figures
S3A, S3B, S3D, S3E, S3G, S3H). This phenotype was consistent
with both the ATG and the splice MOs. To ensure that the
decrease in th and dbh was not secondary to a general delay in
development due to MO injection, we examined the SCG at 4 dpf
(Figures 2A, 2B, 2D, 2E, 2G, 2H) and later (5 dpf; data not
shown), again noting a decrease in the expression of these genes.
To confirm that the phenotype was specific to phox2b, we rescued
the th- and dbh-expressing cells by coexpressing human PHOX2B
mRNA with both MOs, which led to an increase in th and dbh
expression in the SCG (Figures 2C, 2E; 2G, 2H; Figures S3C,
S3F; 3G, 3H). These results indicate that PHOX2B is necessary
and sufficient for the terminal differentiation of sympathetic
neuronal precursors.
The 676delG and K155X variants cause a decrease in
terminal differentiation of sympathetic progenitors
We next examined the effects of three distinct neuroblastoma-
associated PHOX2B mutations on PSNS development (Figure S4,
Figure 3). Overexpression of the 676delG frameshift [5] and K155X
truncation [8] variants led to a significant decrease in the
expression of th (Figure 3D, 3E, 3M) and dbh in the SCG
(Figure 3J, 3K, 3N) as compared to that in control (Figure 3A, 3G)
Figure 1. phox2b is expressed in the SCG, a marker of the peripheral sympathetic nervous system in the zebrafish. (A–D) Whole-mount
in situ hybridization (ISH) for phox2b expression in wild-type embryos at the indicated time points. phox2b expression is seen in cells of the
prospective superior cervical ganglion (SCG; white arrows, boxed) at 36 hpf (A), which start to extend caudally to form the sympathetic chain. These
cells are identified as sympathetic neuronal cells by their expression of dbh and th (E, F). Expression is also seen in the brachial arches (black asterisk)
and hindbrain (white asterisk). By 50 hpf, phox2b expression is seen in the enteric precursors (B–D, black arrow). Expression continues in two parallel
rows caudally, encompassing the sympathetic chain until 4 dpf. (E) Lateral view (cranial to the left) of a 4-dpf zebrafish embryo analyzed by whole-
mount ISH for dbh expression, which is seen in the SCG (black square), the arch associated complex (AAC) also derived from the neural crest, and the
hindbrain (HB). Inset shows enlarged dorsal view of the SCG. (F) Whole-mount ISH of 4-dpf embryo analyzed for th expression. Aggregates of cells
expressing th are seen in the SCG (arrow) as well as in the midbrain (MB), HB and retina (R).
doi:10.1371/journal.pgen.1003533.g001
PHOX2B Mutations Impair PSNS Differentiation
PLOS Genetics | www.plosgenetics.org 3 June 2013 | Volume 9 | Issue 6 | e1003533
and WT (Figure 3B, 3H) phox2b RNA-injected animals, but had a
similar effect to MO knockdown (Figure 3F, 3L). By contrast,
overexpression of the R100L homeodomain missense mutation [7]
did not lead to a discernible change in the expression of either th or
dbh in the SCG (Figure 3C, 3I). To mimic the heterozygous
situation seen in patients with PHOX2B mutations, we repeated
these experiments in the setting of phox2b MO knockdown. In this
context, overexpression of K155X and 676delG led to an even more
striking reduction and, in some embryos, to an almost complete
absence of th and dbh expression in the SCG (Figure 3O, 3P).
These results suggest that the block in differentiation imposed by
the 676delG and K155X mutations cannot be rescued by the
expression of endogenous wild-type phox2b; rather, these variants
appear to function dominant-negatively.
phox2b deficiency prevents retinoic acid-induced
sympathetic progenitor cell differentiation
PHOX2B complements exogenous differentiating agents such as
retinoic acid (RA) by promoting cellular differentiation in vitro
[36]. To determine whether phox2b loss might obviate the
induction of differentiation by RA, we treated control and phox2b
MO embryos with various concentrations of 13-cis-retinoic acid,
which is commonly used in the treatment of patients with
neuroblastoma (Figure 4A–4F). Control-injected embryos showed
an increase in th expression in the SCG after RA treatment
(Figure 4A–4C, 4G), which was not apparent in the SCG of the
phox2b morphant embryos (Figure 4D–4F, 4G). A similar
impairment in RA-induced differentiation was observed after
expression of the 676delG variant and, to a lesser extent, the K155X
variant (Figure 4H–4P). Similar effects in dbh expression were also
seen (data not shown). Together, these findings reinforce the strict
requirement for Phox2b in the differentiation of sympathetic
neuronal progenitors and suggest that loss of this transcription
factor cannot be overcome with RA treatment.
phox2b deficiency induces distinct effects on genes
involved in PSNS differentiation
To assess the impact of decreased phox2b function on the
transcription factors that mediate noradrenergic differentiation in
the zebrafish, we analyzed their expression following MO
knockdown. We observed that mRNA expression of phox2b itself
was markedly increased despite the decrease in Phox2b protein
induced by MO knockdown (Figure 5A, 5B; Figure S5A, S5B).
During normal development in the zebrafish, phox2b expression is
Figure 2. phox2b-deficient embryos show impaired differentiation of sympathetic neurons in the SCG. (A–F) Lateral/oblique views of 4-
dpf embryos after whole-mount ISH for th (A–C) and dbh (D–F) in control and phox2b–deficient embryos. Arrows indicate the SCG. Knockdown of
phox2b by injection of a splice MO (4 ng) (MOsplice) inhibits the expression of th and dbh (B, E) which is rescued by coexpression of human PHOX2B
mRNA (10 ng/ml) (C, F). Relative intensity levels of th (G) and dbh (H) expression in embryos injected with phox2b MOs that inhibit translation (MOATG)
or splicing (MOsplice). Mismatched control MO (MOmm) and PHOX2B mRNA-rescue (MOsplice/PHOX2B) are also shown. Data are presented as means 6
SD (***P,0.001; **P,0.01; n = 15 for each group).
doi:10.1371/journal.pgen.1003533.g002
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first seen in sympathetic ganglia precursors at 36 hpf and, as the
cells undergo differentiation, decreases to lower levels by 4 dpf
(this study), corresponding to E10.5 to E13 in mice [6]. This
increase in phox2b RNA expression on abrogation of the protein is
consistent with studies that Phox2b regulates its own expression
[31]. We also noted that expression of the zebrafish ortholog of
ASCL1, ascl1, was strikingly increased in the SCG in phox2b
morphants (Figure 5C, 5D; Figure S5C, S5D). ascl1 is expressed
only transiently in the SCG with maximal expression at 48 hpf,
decreasing to less than 10% in 3-dpf embryos [18]. The increased
Figure 3. The neuroblastoma-associated 676delG and K155X PHOX2B variants cause decreased terminal differentiation in the SCG.
Whole-mount ISH for th (A–F) and dbh (G–L) expression in 3-dpf embryos in which human neuroblastoma-derived mutations were overexpressed
(lateral views are shown). The area encompassing the SCG (boxed) is shown enlarged to the right of each panel. Capped mRNA (100 ng/ml) for wild-
type (WT) human PHOX2B and the R100L, 676delG, K155X mutations were injected into one-cell embryos. CT, control water-injected. Relative intensity
levels of th (M) and dbh (N) expression in the embryos depicted in panels A–F and G–L respectively. Data are presented as means 6 SD (*P,0.01 vs.
control-injected embryos; n = 6 per group). Whole-mount ISH for th (O) and dbh (P) in 3-dpf embryos expressing the phox2b MO and PHOX2B K155X
mutant mRNA (P2BMO+K155X). Arrow indicates the region of the SCG.
doi:10.1371/journal.pgen.1003533.g003
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expression of ascl1 transcripts in the SCG of phox2b morphants
suggests that Phox2b negatively regulates ascl1 transcription as
well. Similar to the effect seen with phox2b MO knockdown,
overexpression of the neuroblastoma-associated variants also led
to increased ascl1 expression in the SCG, with the 676delG and
K155X mutants inducing higher ascl1 expression than did R100L
Figure 4. Impaired differentiation in the SCG due to phox2b deficiency is not rescued by retinoic acid. (A–F) Dorsal views of 3-dpf
embryos injected with phox2b MO (D–F) or mismatched control MO (A–C) and treated with increasing concentrations of 13–cis retinoic acid (RA). (G)
Relative intensity measurements of th expression in the SCG of embryos injected with various MOs and treated with different concentrations of RA.
ATGK1, translation-blocking phox2b MO; P2BT2, splice blocking phox2b MO. (H–O) Whole-mount ISH of 3-dpf embryos in which the specified RNAs
were overexpressed and analyzed for th expression following exposure to RA. Capped mRNA (100 ng/ml) for wild-type (WT) human PHOX2B, and the
R100L, 676delG, K155X mutations were injected into embryos at the one-cell stage. (P) Quantification of the relative intensity of th staining in the
embryos depicted in H–O. Data are presented as means 6 SD (*P,0.05; n = 10 per group).
doi:10.1371/journal.pgen.1003533.g004
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(Figure 5E–5I). Phox2a, a homologue of Phox2b, that is expressed
downstream of both Ascl1 and Phoxb during murine sympathetic
neural development [13,17] was unchanged in phox2b morphant
embryos (Figure 5J, 5K). Finally, expression of hand2 [19,43],
gata3 [20,44] and tfap2a [21,22], three other transcriptional
regulators implicated in the control of sympathetic neuronal
differentiation [10,18] was decreased on phox2b knockdown
(Figure S5E–J). Overexpression of the 676delG and K155X
variants also led to a decrease in gata3 and tfap2a expression
(Figure S5K–P). Together, these results suggest that these genes
are regulated by phox2b during sympathetic neuronal differenti-
ation and are affected by perturbations in its function.
phox2b deficiency leads to an increase in progenitor cells
in the SCG
We surmised that reduced expression of the th and dbh
noradrenergic differentiation markers in the SCG of phox2b
morphants might reflect either apoptosis of terminally differentiated
sympathetic neurons or the failure of precursors to differentiate.
There was no evidence of an increase in apoptosis in the SCG as
determined by acridine orange staining of phox2b MO-injected
embryos (data not shown). However, simultaneous analysis of th and
phox2b expression by double labeling of the phox2b morphants
showed an increase in phox2b expression with a concomitant
decrease in th expression in the SCG compared to stage-matched
control MO-injected embryos (Figures 6A, 6B). Analysis of these
embryos using qRT-PCR confirmed the presence of significantly
increased phox2b expression in the face of decreased th (Figure 6E).
The same results were obtained when double labeling was
performed with dbh and phox2b, the decrease in dbh-expressing cells
being accompanied by increased expression of phox2b in morphants
compared to controls (Figures 6C, 6D). We were unable to test
whether this was also true in embryos in which PHOX2B variants
were overexpressed because the high level of sequence homology
between human and zebrafish phox2b made it difficult to interpret
the results. To confirm that these phox2b- and ascl1-expressing SCG
cells were arrested early in differentiation, we analyzed the
expression of elavl3 (HuC), the well-characterized, evolutionarily
conserved neural differentiation marker that is normally only
detected in mature postmitotic neurons and has been used to
Figure 5. Deficiency of Phox2b protein due to either MO knockdown or overexpression of PHOX2B variants leads to increased
phox2b and ascl1 RNA expression in the SCG. (A–D) Dorsal views (cranial to the left) of 4-dpf embryos expressing a phox2b ATG MO (B,D) or
mismatched control MO (A,C), showing expression of phox2b (A, B) and ascl1 (C, D) as determined by whole-mount ISH. Insets depict an enlarged
view of the area of the SCG. (E–I) Area of the SCG is shown in 4-dpf embryos (lateral view, cranial to the left) in which capped mRNA (100 ng/ml) for
wild-type (WT) human PHOX2B (F) and the indicated variants (G–I) was injected and ISH performed for ascl1. CT, control, water injected. (J, K) Whole-
mount ISH in control vs. phox2b MO-injected embryos double labeled with phox2a (blue) and th (red) riboprobes. Arrows point to the SCG.
doi:10.1371/journal.pgen.1003533.g005
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demonstrate neuronal differentiation in the zebrafish [41,45–47]
(Figures 6F–6K). We observed a decrease in elavl3 expression in the
phox2b morphants compared to controls, with the extent of
reduction comparable to that of th and dbh, suggesting that the
SCG is populated mainly by undifferentiated cells. Overexpression
of the 676delG and K155X mutants, but not R100L, also led to a
decrease in elavl3 expression in the SCG of these embryos
(Figures 6H–K). Together, these data suggest that a decrease in
Phox2b levels, either through MO knockdown or overexpression of
dominant-negative mutations, blocks sympathetic cells at a progen-
itor stage marked by high phox2b and ascl1 expression. Such cells
cannot proceed to the next developmental stage, involving hand2,
gata3 and tfap2a, and therefore cannot undergo terminal PSNS
differentiation characterized by the expression of th and dbh.
ascl1 is not essential for differentiation of SCG cells in
zebrafish
During noradrenergic development in the chick embryo, Phox2b
and Ascl1 are expressed together in response to BMP signaling
[44,48]; in fact, elimination of Ascl1 has also been reported to cause
impaired sympathetic differentiation [14,16]. To determine wheth-
er ascl1 is as critical as phox2b to PSNS differentiation in the
zebrafish, we studied the effects of ascl1 knockdown using a
translation-blocking MO (Figure S6A; Figure 7A, 7B, 7C, 7E).
Abrogation of ascl1 alone led to only a marginal decrease in th and
dbh expression in the SCG (Figure 7B, 7E, 7G), while a striking
decrease in both th and dbh expression occurred with simultaneous
knockdown of both ascl1 and phox2b, similar to the result with phox2b
knockdown alone (Figure 7C, 7F, 7G). Moreover, in contrast to the
outcome of phox2b knockdown, expression of hand2, gata3 and tfap2a
was not affected in the ascl1 morphants (Figure S6B–G). These
findings identify Phox2b as the central driver of terminal
differentiation of sympathetic neurons in the zebrafish model.
ascl1 does not regulate phox2b in zebrafish
Observations in murine models have revealed that PHOX2B and
ASCL1 cross regulate each other [6,14,16,49]. The fact that ascl1
expression was significantly increased in the phox2b morphants
Figure 6. Phox2b deficiency causes arrest of SCG cells at an undifferentiated stage. (A,B) Dorsal views of ISH with FITC-labeled th (red) and
digoxigenin-labeled phox2b (blue) riboprobes on 4-dpf embryos in which phox2b expression was abrogated by MO knockdown. Arrows point to the
SCG. Insets show enlarged views of the SCG. (C, D) Lateral views of ISH with FITC-labeled phox2b (red) and digoxigenin-labeled dbh (blue) riboprobes
in MO-injected (D) and control (C) embryos. (E) Quantitative real time-PCR analysis comparing phox2b mRNA expression levels in control vs. phox2b
MO-injected (P2BATG MO) embryos. Data are presented as means6 SD (****P,0.0001, ***P,0.001; n = 15 per group). (F,G) Whole-mount ISH for elavl3
in the area of the SCG (arrow) in phox2b MO-injected (G) compared to control MO-injected embryos at 4-dpf (F). (H–K) Lateral views of the SCG in 4-
dpf embryos overexpressing the indicated RNAs analyzed for elavl3 expression by whole-mount ISH.
doi:10.1371/journal.pgen.1003533.g006
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suggested a regulatory effect of phox2b on ascl1 (Figure 5C,5D). To
determine if Ascl1 had the same effect on phox2b in the zebrafish
model, we studied the effects of ascl1 knockdown on phox2b
expression. While causing a decrease in its own expression at both
the RNA and protein levels (Figure 7H, 7I, Figure S6A), knockdown
of ascl1 had no effect on phox2b expression (Figure 7K, 7L).
Similarly, overexpression of ascl RNA also did not affect phox2b
expression (Figure S6H, S6I). However, knockdown of both genes
simultaneously led to a striking increase in ascl1 (Figure 7J) and
phox2b (Figure 7M) mRNA expression in the SCG. These results
suggest that although Phox2b is capable of regulating ascl1 in the
zebrafish model, the latter does not have any appreciable impact on
phox2b. Rather, Ascl1 appears to primarily regulate phox2a. Unlike
knockdown of phox2b, which did not affect phox2a expression, we
observed a significant reduction in phox2a expression in the SCG
following ascl1 knockdown (Figure 7N, 7O). These results are
consistent with the finding that Ascl1 is required for the expression
of Phox2a in sympathetic and parasympathetic murine ganglionic
anlagen [14,16], with Phox2b assuming a less important role.
Discussion
In this study, we relied on a zebrafish model of PSNS
development to demonstrate that a reduction in phox2b expression
due to MO knockdown or overexpression of the neuroblastoma-
associated 676delG frameshift and K155X truncation variants of
PHOX2B inhibits the terminal differentiation of sympathetic
neuron progenitors (Figure 8). Our findings indicate that intact
Phox2b function is essential for the normal development of cells in
the sympathetic ganglia, and that in the context of phox2b
deficiency, differentiation cannot be induced by exogenous agents.
In contrast to the remainder of the nervous system, where the
onset of neuronal differentiation is coupled with cell cycle exit, an
increase in the number of sympathetic neurons during develop-
ment reflects the proliferation of differentiated sympathetic
neurons rather than the proliferation and subsequent differenti-
ation of neuronal progenitors [50,51]. Indeed, studies in the chick
embryo have revealed that the vast majority of postmitotic
sympathetic neurons are generated through the proliferation of
already differentiated neurons [50–53]. An alteration in Phox2b
function in the zebrafish, by either MO knockdown or overex-
pression of certain neuroblastoma-associated variants, led to a
block in the differentiation of sympathetic progenitor cells. First,
there was a large increase in phox2b transcript-expressing cells at
the expense of th- and dbh-expressing cells in the SCG (Figure 6).
Second, these phox2b-expressing cells were unable to proceed to
subsequent differentiation steps, even when stimulated with RA,
whose signaling can induce noradrenergic differentiation in the
Figure 7. phox2b, but not ascl1, is indispensable for sympathetic neuronal differentiation. (A–F) Whole-mount ISH of 3-dpf embryos for th
and dbh following ascl1 MO knockdown. Lateral views depict a minimal decrease in expression of th (A,B) and dbh (D,E) in ascl1 MO-injected embryos
compared to control MO-injected (A,D) embryos. Simultaneous knockdown of both ascl1 and phox2b led to a significant decrease in expression of th
and dbh in the SCG (C,F). (G) Relative intensity levels of dbh-staining in the SCG of embryos expressing ascl1 MO, phox2b MO or the combination of
the two. Data are presented as means6 SEM (***P,0.001; n = 15 per group). (H–M) Whole-mount ISH for expression of ascl (H–J) and phox2b (K–M) in
embryos in which ascl1 expression was abrogated by MO knockdown, either singly (I, L) or in combination with phox2b (J, M). (N,O) Whole-mount ISH
for phox2a expression in 4-dpf embryos in which ascl1 expression was abrogated by MO knockdown. Arrows point to region of SCG.
doi:10.1371/journal.pgen.1003533.g007
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zebrafish (Figure 4) [21]. Third, in addition to decreased th and dbh
expression, the SCG cells also showed reduced expression of the
mature neuronal marker elavl3 (Figure 6).
In our study, specific types of PHOX2B variants exhibited
distinct effects on sympathetic neuronal differentiation, with the
R100L missense mutation lacking an effect on differentiation,
while the 676delG frameshift and K155X truncation mutations
exhibited impaired differentiation, an effect that was all the more
prominent with simultaneous MO knockdown. Findings similar to
ours were reported by Reiff et al (2010) on overexpression of the
K155X mutation in primary chick sympathetic neuron cultures,
although in this system the 676delG variant lacked any apparent
effect on the expression of terminal differentiation markers [30]. In
agreement with our data, another group reported resistance to
differentiation with RA in human neuroblastoma cells engineered
to express the 676delG variant (in the presence of endogenous
PHOX2B) [36]. The R100L homeodomain variant, on the other
hand, did not appear to affect sympathetic neuronal differentiation
in the zebrafish, similar to findings in the above mentioned study
in avian sympathetic neurons, where this mutant elicited increased
cell proliferation only [30].
The basis for the varied effects of distinct mutations on
sympathetic neuronal differentiation is not entirely clear. To some
extent, they reflect intrinsic differences between the in vitro and in
vivo models in which the variants were tested, as well as different
degrees of forced or blocked expression in target cells. Ultimately,
however, the impact of PHOX2B mutants on the differentiation of
immature sympathetic neurons depends on the protein structures
that are modified. The R100L missense variant, for example, is
defined by a minimal change in its homeodomain, whereas both
676delG and K155X possess modifications due to an altered reading
frame or deletion of critical coding sequences within the C-
terminus, respectively, either of which can lead to the disruption of
essential protein-protein interactions or, in some instances, to novel
interactions not seen with the WT protein. Indeed, misfolding and
oligomerization have been demonstrated with frameshift mutations
of PHOX2B and cellular mislocalization and cytoplasmic aggrega-
tion with truncated variants [54]. The 693del8 frameshift mutant,
for example, is thought to interact with proteins that do not bind to
the WT protein [38]. Similarly, we have noted that the 676delG and
K155X variants do not bind to certain proteins recognized by WT
PHOX2B, resulting in impaired neuroblastoma cell differentiation
(George et al, unpublished observations). Thus, it is not surprising
that the K155X truncation mutation, unlike the R100L missense
change, generates a protein that not only stimulates sympathetic
neuron proliferation [30], but also has a dominant–negative
inhibitory effect on cell differentiation.
Furthermore, since both frameshift and truncation changes in
the PHOX2B gene appear to generate stable proteins that lack the
transactivation potential of WT PHOX2B, [30,36,37,55] their
contribution to neuroblastoma predisposition could be twofold. By
interacting with different modifier proteins, these mutants could
preserve the ability of PHOX2B to suppress cellular proliferation
while abolishing its pro-differentiation regulatory effects. At the
same time, as has been shown previously [30] these transactiva-
tion–impaired variants likely compete with intact PHOX2B for
critical promoter sequences on neuronal differentiation-linked
target genes, resulting in a dominant-negative repressive effect on
their expression. This hypothesis is supported by the failure of the
WT phox2b to rescue the arrested differentiation of sympathetic
neuronal progenitors expressing either the 676delG or K155X
variants.
The gene dosage of PHOX2B also appears to have played a role
in determining the disease phenotype in our study. Indeed, fish
with MO knockdown of phox2b but no mutations or deletions
consistently showed arrested differentiation of sympathetic neuro-
nal progenitors. This result would account for a neuroblastoma
case recently reported by Jennings et al [35] in which a
heterozygous deletion of PHOX2B was associated with both
CCHS and a neural crest tumor. Thus, PHOX2B deficiency due to
whole-allele deletion should be considered another mechanism
whereby individuals might acquire a predisposition to neuroblas-
toma. The precise oncogenic mechanism of PHOX2B deficiency
and its associated phenotypes will require additional study, but it
seems likely that dosage reduction beyond 50% (sub-haploinsuffi-
ciency) may be required, as mice that were haploinsufficient for
Phox2b did not develop tumors [56].
Neuroblastoma development in TH-MYCN transgenic mice
begins with hyperplastic lesions in early postnatal sympathetic
ganglia that are composed predominantly of Phox2b-positive but
Th-negative neuronal progenitors [28]. This indicates a central
role for aberrant PHOX2B regulation of immature sympathetic
neurons in neuroblastoma predisposition. Our studies suggest a
model (Figure 8) in which aberrant PHOX2B function through
either allelic deletion or dominant-negative mutations promote the
same endpoint: impaired differentiation of sympathetic neuronal
progenitor cells while promoting the expansion of a population of
undifferentiated cells likely to be susceptible to so-called second
‘‘hits’’ such as MYCN amplification.
Materials and Methods
Ethics statement
All experiments involving zebrafish conformed to the regulatory
standards and guidelines of the Dana-Farber Cancer Institute
Figure 8. Schematic representation of the effect of aberrant
Phox2b on sympathetic neuronal development in the zebra-
fish model. Phox2b is the master regulator of a differentiation cascade
involving Hand2, Gata2/3 and Tfap2a that ultimately leads to terminal
differentiation of neuron progenitors, marked by dbh and th expression.
Phox2b regulates itself as well as ascl1a and can directly activate dbh. A
decreased dosage of the phox2b gene, either by allelic deletion (Phox2b
KD) or by dominant-negative mutations (676delG or K155X) can
compromise normal Phox2b function so that the cells are unable to
progress through the various developmental stages and instead remain
in an undifferentiated state.
doi:10.1371/journal.pgen.1003533.g008
PHOX2B Mutations Impair PSNS Differentiation
PLOS Genetics | www.plosgenetics.org 10 June 2013 | Volume 9 | Issue 6 | e1003533
(DFCI) and the Brigham and Women’s Hospital (BWH) Institu-
tional Animal Care and Use Committee.
Fish husbandry and strains
Zebrafish were maintained at the DFCI and BWH zebrafish
facilities under standard conditions [57]. Embryos were raised in E3
medium supplemented with 0.003% 1-phenyl-2-thiourea (PTU) at
28.5uC to allow visualization of internal structures. The p532/2
mutant allele tp53M214K/M214K was kindly provided by A. Thomas
Look [42]. tp53M214K/M214K and wild-type embryos of the AB strain
were obtained by natural group mating. The embryos were staged
according to established morphological criteria [57].
Morpholino injections
Morpholinos (MOs) were obtained from GeneTools, LLC
(Philomath, OR) based on the published GenBank sequences for
phox2b and ascl1 (phox2b P2BT2 splice donor: 59-AAGTAAGCG-
GAGAATGTCCCACCTG; mismatched phox2b P2BT2 splice
donor: AcTAAcCGGAcAATcTCCgACCTG; phox2b ATG: 59-
TATACATTGAAAAGGCTCAGTGGAG; mismatched phox2b
ATG: TATAgATTcAAAAccCTCAcTGGAG; ascl1 ATG: 59-
CCATCTTGGCGGTGATGTCCATTTC; mismatched ascl1
ATG: CCATgTTGGCcGTcATcTCgATTTC). For knockdown
of phox2b, two nonoverlapping MOs were used (ATGK1, designed
to target the start site; and P2BT2, designed to block splicing at the
phox2b exon 2-intron 2 boundary). Embryos at the one to two-cell
stages were injected with up to 4 ng of MO diluted with 16
Danieau’s solution with Phenol Red. Injected embryos were raised
to 12, 24, 36, 72, 96 and 120 hpf and processed for in situ
hybdridization. Generalized nonspecific necrosis in MO-injected
and mismatched control MO-injected AB embryos was alleviated
using the tp53M214K/M214K strain [42]. MO concentrations were
optimized so that the lowest amount necessary to retain the
normal phenotype while demonstrating effects of absent phox2b
expression was used. The observed phenotypes were consistent
between the ATG and splice MO. Care was taken to stage-match
the embryos as much as possible with mismatched MO-injected
controls so as to eliminate phenotypes due to developmental delay.
Capped RNA overexpression
Human PHOX2B (a generous gift from K-S Kim) and the
PHOX2B mutant 676delG (kindly provided by J. Maris) were
subcloned into the pCS2+ vector. Site directed mutagenesis was
used to generate PHOX2B mutant constructs R100L and K155X
using the Quickchange II Site-directed mutagenesis kit (Strata-
gene). ascl1 was amplified from a whole embryo cDNA library and
cloned into pCS2+. The SP6 Message machine kit (Ambion) was
used to transcribe synthetic capped RNA. Embryos were injected
with 50–100 pg of mRNA at the one- to two-cell stages. Injected
embryos were raised at different time points ranging from 12 hpf
to 4 dpf and fixed with 4% paraformaldehyde for in situ
hybridization.
Antisense probes
The following antisense RNA probes were generous gifts:
phox2b and phox2a (S. Guo), dbh and elavl3 (J-S Lee). Other probes
(th, ascl1, tfap2a, hand2, gata3) were generated by amplifying the
Danio rerio ORFs from a whole embryo cDNA library using PCR
primers based on published GeneBank sequences. The PCR
products were subcloned into the EcoRI/XhoI sites of pCS2+
vector. Following sequence verification, antisense riboprobes
were generated by in vitro transcription with DIG RNA labeling
kit Sp6/T7 (Roche).
Whole-mount in situ hybridization and
immunofluorescence
Embryos at different developmental stages were collected and
fixed in 4% (w/v) paraformaldehyde (Sigma). Whole-mount in situ
hybridization was performed as described [58]. Images of
zebrafish embryos were taken using an Olympus SZX12
microscope and a digital camera.
Intensity measurements
Intensity measurements were performed using Image-Pro Plus
(IPP) software (MediaCybernetics, PA). Identical regions were
selected using the rectangle tool set to a constant area. Mean
optical density (MOD) and total per area (TPA) in boxed areas
were used for pixel intensity. Differences between two groups were
analyzed using Student’s t-test.
Retinoic acid treatment
At 2 or 3 dpf embryos injected with a control MO and phox2b
MO, were subjected to 13-cis retinoic acid treatment for 24 hrs at
three concentrations 1 nM, 10 nM, and 100 nM diluted in PTU
egg water. DMSO was used as a control. Embryos were then fixed
and gene expression was analyzed using in-situ hybridization.
RT-PCR
Embryos were homogenized in TRIzol reagent by passing
through a 22G needle. Total RNA was extracted as described in
the manufacturer’s instructions (Invitrogen). Primer pairs encom-
passing the full-length phox2b gene were designed and used to
amplify phox2b in the MO-injected embryos with the Superscript
First strand synthesis kit (Invitrogen). 50 pg of 1st strand cDNA
was used to amplify phox2b using the Expand High Fidelity Plus
PCR system (Roche).
Western blotting
Immunoblotting was performed according to standard methods.
The following antibodies were used: anti-PHOX2B (Santa Cruz,
N14 cat# sc-48627), anti-ASCL1 (Santa Cruz, sc-28688 ASCL1-
H56). Anti-beta tubulin antibody (Abcam 6046-100) was used as a
loading control.
Supporting Information
Figure S1 Zebrafish phox2b is highly homologous to human
PHOX2B. (A) RT-PCR analysis of phox2b RNA expression in
whole embryos at the indicated time points. (B) Western blot
analysis of zebrafish Phox2b expression. (C) Phylogenetic tree
depicting high conservation of phox2b among species. (D). Protein
sequence alignment showing complete conservation of the
homeodomain (HD, boxed) and the first polyalanine repeat (Ala
1) between human and zebrafish PHOX2B. The second
polyalanine repeat, Ala 2, is absent in the zebrafish.
(TIF)
Figure S2 Abrogation of Phox2B expression by morpholino
knockdown. (A) Schema of the genomic structure of the phox2b
gene depicting the two morpholino (MO) sequences, a translation-
blocking morpholino, MOATG, and a splice-blocking morpholino,
MOsplice, targeted to the splice junction of the second exon. Exons
are numbered 1, 2 and 3. The shaded boxes indicate the
homeodomain. (B) Western analysis (left panel) of Phox2b
expression in wild-type uninjected (WT), mismatched control
MO-injected (ctrl MO) and phox2b MO-injected (MOATG)
embryos at the indicated time points. RT-PCR analysis (right
panel), of 3-dpf embryos injected with either mismatched control
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MO (mm MOsplice) or phox2b splice MO (MOsplice) depicting a
larger transcript (in addition to the WT phox2b) in the splice MO-
injected embryos. Sequencing of the larger transcript revealed the
inclusion of the second intron as shown in the accompanying
schema. This transcript contained a stop codon (*) 40 bp into the
second intron, leading to a truncated protein lacking the third
exon. (C) The use of tp532null embryos leads to a reduction in
head necrosis and nonspecific morphological changes due to MO
injection. Phenotypes of AB embryos show head necrosis and tail
deformities (arrows) at 24 hpf and at 3 dpf after injection with
Phox2b translation blocking (MOATG), splice blocking (MOSplice)
and to a lesser extent, mismatched control MOs (mm MOATG)
compared with uninjected (U) embryos. These defects are
minimized in the tp53 homozygous null background (tp53M214K/
M214K) animals at 24 hpf and more obviously during later stages.
(TIF)
Figure S3 Phox2b knockdown leads to a significant decrease in
the expression of terminal differentiation markers in the SCG.
Whole mount ISH of th and dbh in 3-dpf embryos in which phox2b
was abrogated by either a translation-blocking MO (B, ATGK1)
or a splice-blocking MO (E, P2BT2) compared with control-MO
injected (mmATGK1 and mmP2BT2) animals (A, D). Rescue of
decrease in th and dbh expression with co-injection of human
PHOX2B RNA (100 pg/ml) with either the translation-blocking
Phox2b MO (C, ATGK1) or the splice-blocking MO (F, P2BT2).
Relative intensity levels of th (G) and dbh (H) expression. Data are
presented as means6 SD (*P,0.05, **P,0.01, ***P,0.001; n= 15
per group).
(TIF)
Figure S4 Schema of selected PHOX2B mutations reported in
patients with neuroblastoma. Variants tested in this study are
marked in bold. Mutations R100L and R141G [7] are both located
within the homeodomain. The 676delG mutation [5] causes a
frameshift and a premature stop, producing a slightly smaller
protein containing only the first polyalanine tract. K155X (A463T)
[8] encodes a premature stop codon and is predicted to produce a
truncated protein missing the third exon (which contains both
polyalanine tracts). NB, neuroblastoma; HSCR, Hirschprung’s
disease; CCHS, congenital central hypoventilation syndrome.
(TIF)
Figure S5 Aberrant phox2b expression leads to differential
expression of genes involved in development of the noradrenergic
lineage in the SCG. (A–D) Whole mount ISH for phox2b (A,B) and
ascl1 (C,D) at 3-dpf in embryos injected with phox2b MO (B,D) or
mismatched control MO (A, C). Lateral views are shown, head to
the left. (E–J) Whole mount ISH for the indicated probes in 3-dpf
embryos in which phox2b expression was abrogated by MO
knockdown. (K–P) Whole mount ISH for gata3 (K–M) and tfap2a
(N–P) expression in 4-dpf embryos in which the indicated mRNAs
were injected. CT, control mRNA.
(TIF)
Figure S6 Alteration of ascl1 levels does not affect the expression
of phox2b or of genes involved in sympathetic neuronal
differentiation. (A) Western analysis of Ascl1 expression in 72-
hpf embryos injected with either control-MO (MM) or ascl1 MO
(ascl1 MO). (B–G) Whole mount ISH for hand, (B,C) gata3 (D,E),
and tfap2a expression in 4-dpf embryos in which ascl1 expression
was abrogated by MO knockdown. Arrows point to the area of the
SCG. (H, I) Whole mount ISH for phox2b expression in 4-dpf
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